Enders G C, Henson J H, Millette C F
J Cell Biol. 1986 Sep;103(3):1109-19. doi: 10.1083/jcb.103.3.1109.
We have examined the adhesion of primary Sertoli cells to a seminiferous tubule basement membrane (STBM) preparation in vitro. The STBM isolation procedure (Watanabe, T.K., L.J. Hansen, N.K. Reddy, Y.S. Kanwar, and J.K. Reddy, 1984, Cancer Res., 44:5361-5368) yields segments of STBM that retain their histotypic form in both three-dimensional tubular geometry and ultrastructural appearance. The STBM sleeves contain two laminae: a thick, inner basal lamina that was formed in vivo between Sertoli cells and peritubular myoid cells; and a thinner, outer basal lamina that was formed between myoid cells and sinusoidal endothelial cells. Characterization by immunofluorescence and SDS PAGE revealed that the isolated STBM retained fibronectin, laminin, and putative type IV collagen among its many components. When the STBM sleeves were gently shaken with an enriched fraction of primary Sertoli cells, the Sertoli cells bound preferentially to the lumenal basal lamina at the ends of the STBM sleeves. Few Sertoli cells bound to either the outer basal lamina of the STBM sleeves or to vascular extracellular matrix material which contaminated the STBM preparation. 3T3 cells, in contrast, bound to all surfaces of the STBM sleeves. Pretreatment of the STBM sleeves with proteases, 0.1 M Na metaperiodate, 4 M guanidine HCl, or heating to 80 degrees-90 degrees C inhibited lumenal Sertoli cell binding, but binding was not inhibited by chondroitinase ABC, heparinase, hyaluronidase, or 4 M NaCl. The lumenal Sertoli cell binding occurred in the presence or absence of added soluble laminin, but not fibronectin. The addition of soluble laminin, but not fibronectin, restored random binding of Sertoli cells to trypsinized STBM sleeves. Our in vitro model system indicates that Sertoli cells recognize differences in two basal laminae produced in vivo on either side of myoid cells.
我们已经在体外研究了原代支持细胞与生精小管基底膜(STBM)制剂的黏附情况。STBM分离程序(渡边,T.K.,L.J. 汉森,N.K. 雷迪,Y.S. 坎瓦尔,以及J.K. 雷迪,1984年,《癌症研究》,44:5361 - 5368)产生的STBM片段在三维管状结构和超微结构外观上都保留了它们的组织型形态。STBM套管包含两层:一层较厚的内基底膜,它在体内形成于支持细胞和睾丸周肌样细胞之间;以及一层较薄的外基底膜,它形成于肌样细胞和窦状内皮细胞之间。通过免疫荧光和SDS - PAGE进行的表征显示,分离出的STBM在其众多成分中保留了纤连蛋白、层粘连蛋白和假定的IV型胶原蛋白。当将STBM套管与原代支持细胞的富集部分轻轻摇晃时,支持细胞优先结合到STBM套管末端的腔内基底膜上。很少有支持细胞结合到STBM套管的外基底膜或污染STBM制剂的血管细胞外基质材料上。相比之下,3T3细胞结合到STBM套管的所有表面。用蛋白酶、0.1 M偏高碘酸钠、4 M盐酸胍预处理STBM套管,或加热到80摄氏度 - 90摄氏度会抑制腔内支持细胞的结合,但软骨素酶ABC、肝素酶、透明质酸酶或4 M氯化钠不会抑制结合。腔内支持细胞的结合在添加或不添加可溶性层粘连蛋白的情况下都会发生,但添加纤连蛋白时不会。添加可溶性层粘连蛋白而非纤连蛋白可恢复支持细胞对胰蛋白酶处理过的STBM套管的随机结合。我们的体外模型系统表明,支持细胞能够识别在体内肌样细胞两侧产生的两种基底膜之间的差异。